OTC · Industrials

Vitaspring Biomedical Co. Ltd. (VSBC)

Vitaspring Biomedical Co. Ltd. brought in $0 of revenue over the twelve months to July 31, 2026. It posted a net loss of $455.6K. At July 31, 2026 it held $13.4K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 17, 2026.

Watch VSBC in 60 seconds

Price

$0.01

0.00% on the day · September 25, 2026

52-week range $0.01 to $1.00

Market cap

$2.3M

Revenue (last 12 months)

What Vitaspring Biomedical Co. Ltd. does

Vitaspring Biomedical Co. Ltd. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on OTC under the ticker VSBC.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2026	$0	-$385.4K	-$415.4K	$0.00	n/a
2025	$0	-$679.9K	-$774.9K	$0.00	n/a
2024	$0	-$1.1M	-$1.1M	-$0.01	n/a
2023	$0	-$4.2M	-$4.2M	-$0.02	-$77.6K
2021	$5.6M	$1.1M	$909.6K	$0.00	-$342.6K
2021	$248.2K	$425.4K	$425.4K	$0.00	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 2, 2026.

Estimated from its filing rhythm: about 45 days after its last report of September 17, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Vitaspring Biomedical Co. Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 17, 2026
Quarterly report 10-Q · period to July 31, 2026Diluted EPS $0.00 versus $0.00.
September 15, 2026
Late quarterly report notice NT 10-Q
September 10, 2026
Executive or director change 8-K
June 17, 2026
Annual report 10-K · period to January 31, 2026Diluted EPS $0.00 versus $0.00.
June 17, 2026
Quarterly report 10-Q · period to April 30, 2026Diluted EPS $0.00 versus $0.00.
June 17, 2026
Quarterly report 10-Q · period to October 31, 2025Diluted EPS $0.00 versus $0.00.
June 17, 2026
Quarterly report 10-Q · period to July 31, 2025Diluted EPS was $0.00.
June 15, 2026
Quarterly report 10-Q · period to April 30, 2025Diluted EPS was $0.00.
June 8, 2026
Annual report 10-K · period to January 31, 2025Diluted EPS $0.00 versus -$0.01.
May 6, 2026
Quarterly report 10-Q · period to October 31, 2024Diluted EPS was $0.00.

All filings on SEC EDGAR

Questions about VSBC

What does Vitaspring Biomedical Co. Ltd. do?

Vitaspring Biomedical Co. Ltd. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on OTC under the ticker VSBC.

Is Vitaspring Biomedical Co. Ltd. profitable?

No. Over the twelve months to July 31, 2026 it reported a net loss of $455.6K.

How much revenue does Vitaspring Biomedical Co. Ltd. make?

Over the twelve months to July 31, 2026 Vitaspring Biomedical Co. Ltd. reported revenue of $0.

When did Vitaspring Biomedical Co. Ltd. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on September 17, 2026. It covers the period to July 31, 2026.

Similar companies

Charles River Laboratories International, Inc.

MEDP

Medpace Holdings, Inc.

NOTVQ

Inotiv, Inc.

Compare VSBC with

Compare VSBC with any company

Follow VSBC

Get an email when Vitaspring Biomedical Co. Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow VSBC: get an email when it files

Where the numbers come from

Financial figures are the values Vitaspring Biomedical Co. Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.